The neuroprotective efficacy of the DPP-4 inhibitor linagliptin against stroke is not mediated by GLP-1 receptor activation

被引：0
|
作者：
Darsalia, V. [1 ]
Larsson, M. [1 ]
Nathanson, D. [1 ]
Drucker, D. J. [2 ,3 ]
Nystrom, T. [1 ]
Klein, T. [4 ]
Patrone, C. [1 ]
机构：
[1] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Internal Med, Stockholm, Sweden
[2] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5S 1A1, Canada
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
71
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [1] The DPP-4 Inhibitor Linagliptin Improves Cardiac Function in GLP-1 Receptor Knockout Mice with Hypertrophic Heart Failure
    Batchu, Sri N.
    Kabir, Golam
    Klein, Thomas
    Connelly, Kim A.
    DIABETES, 2016, 65 : A127 - A127
  • [2] Global View on Safety and Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors
    Timofte, L.
    Stratmann, B.
    Bojita, M. T.
    Quester, W.
    Tschoepe, D.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (01): : 19 - 27
  • [3] Gastrointestinal and Renal Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFEGUARD Trial
    Mraz, Milos
    Klouckova, Jana
    Kavalkova, Petra
    Trachta, Pavel
    Krizova, Jarmila
    Kosak, Mikulas
    Kurzova, Ivana
    Kocna, Petr
    Haluzik, Martin
    DIABETES, 2016, 65 : A284 - A284
  • [4] The DPP-4 Inhibitor Linagliptin Restores β-Cell Function and Survival in Human Isolated Islets Through GLP-1 Stabilization
    Shah, Payal
    Ardestani, Amin
    Dharmadhikari, Gitanjali
    Laue, Svenja
    Schumann, Desiree M.
    Kerr-Conte, Julie
    Pattou, Francois
    Klein, Thomas
    Maedler, Kathrin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (07): : E1163 - E1172
  • [5] Cardiovascular Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFE-GUARD Trial
    Mraz, Milos
    Chytilova, Eva
    Klouckova, Jana
    Trachta, Pavel
    Skrha, Jan, Jr.
    Krizova, Jarmila
    Petrak, Ondrej
    Krupicka, Jan
    Tuka, Vladimir
    Kudlicka, Jaroslav
    Kratka, Zuzana
    Dostalova, Gabriela
    Malik, Jan
    Haluzik, Martin
    DIABETES, 2016, 65 : A284 - A284
  • [6] Co-Administration of the DPP-4 Inhibitor Linagliptin and Native GLP-1 Induce Body Weight Loss and Appetite Suppression
    Hansen, Henrik
    Hansen, Gitte
    Paulsen, Sarah
    Mark, Michael
    Vrang, Niels
    Klein, Thomas
    DIABETES, 2013, 62 : A309 - A309
  • [7] Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review
    Bihan, Helene
    Ng, Winda L.
    Magliano, Dianna J.
    Shaw, Jonathan E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 121 : 27 - 34
  • [8] Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
    Aroda, Vanita R.
    Henry, Robert R.
    Han, Jenny
    Huang, Wenying
    DeYoung, Mary Beth
    Darsow, Tamara
    Hoogwerf, Byron J.
    CLINICAL THERAPEUTICS, 2012, 34 (06) : 1247 - 1258
  • [9] GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?
    Scheen, Andre J.
    ANNALES D ENDOCRINOLOGIE, 2013, 74 (5-6) : 515 - 522
  • [10] DPP-4 inhibitors and GLP-1 receptor agonists. Cardiovascular effects
    Nauck, M. A.
    El Aziz, M. S. Abd
    Meier, J. J.
    DIABETOLOGE, 2016, 12 (03): : 184 - +
12345